High-Growth Two-Location Medical Oncology Practice | Southwestern U.S. | Infusion & In-House Pharmacy

Seller Overview:
Seller States: This offering represents the opportunity to acquire a well-established, high-growth medical oncology practice with two locations in separate Southwestern states, each serving a distinct patient population. The primary location has operated for approximately 18 years and includes an in-house pharmacy, infusion suite, and Lab-corp, while the second location was established approximately four years ago to expand into an additional market.

Both offices are fully staffed and operate five days per week, with Nurse Practitioners, Physician Assistants, and Medical Assistants ensuring continuity of care and an uninterrupted service. The practice also maintains an experienced in-house billing team.

The seller, the sole oncologist, currently maintains a progressive clinical schedule across both locations. Significant growth opportunities exist through the future addition of provider, expanded clinic hours, and increased infusion and pharmacy volume.

Revenue is primarily derived from infusion services (~80%), including chemotherapy, and specialty pharmacy with approximately 14% generated from Evaluation & Management visits. Additional revenue streams include in-office procedures such as bone marrow biopsies. The in-house pharmacy operates at both primary locations (inventory not included in the sale).

The practice participates with Medicare and most major commercial insurers, providing a diversified and stable reimbursement base.

Growth Opportunities:
• Expand clinical capacity through additional physicians and/or APPs
• Increase infusion utilization and in-house pharmacy revenue
• Further penetrate two distinct and underserved regional markets
• Addition of imaging services and radiation therapy

Operations & Transition:
• Tenured, experienced clinical and administrative teams in place at both locations
• Established referral relationships and strong reputations in each community
• Efficient, scalable workflows to support a seamless ownership transition
• Seller available for 1–2 years to assist with transition, payer relationships, and growth initiatives

Services Provided:
• Medical oncology
• Hematology
• Chemotherapy and specialty infusions
• Immunotherapy
• Bone marrow biopsies
• Evaluation & Management (E&M) services
• Clinical research (included in this transaction) has increased from four (4) studies in 2025 to eleven (11) in 2026.

Investment Highlights:
• 2025 Gross Revenue of $19M+ with $2.17M+/- SDE & $1.62M+/-Adjusted EBITDA. 2026 is trending substantially higher than 2025.
• Two fully operational, modern facilities in separate Southwestern states
• High-margin, infusion-driven revenue model with ancillary pharmacy income
• Fully staffed, turnkey platform with capacity for provider expansion
• Significant upside through adding a full-time oncologist, expanding clinic hours, and increasing infusion and pharmacy volume

Additional Information:
Serious inquiries only. This medical practice operates in a regulated industry. Prospective buyers should have relevant industry experience and understand the applicable licensing and regulatory requirements.

Execution of a Non-Disclosure Agreement (NDA) and proof of funds are required prior to the release of confidential information.

One Southwest practice location is represented by First Choice Business Brokers Phoenix #213 #101, Dr. Fernando Acosta, Owner/Business Broker/Agent (AZ R.E. Lic.# LC68988001 | SA691260000) and Dr. Leilani Felix- Acosta, Owner/Business Broker (AZ R.E. Lic. #LC68988001 | SA693611000. The other Southwest practice location is represented by a separate licensed brokerage in that state.